503 related articles for article (PubMed ID: 25874959)
1. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy.
Di H; Wu H; Gao Y; Li W; Zou D; Dong C
Drug Dev Ind Pharm; 2016 Dec; 42(12):2038-2043. PubMed ID: 27184819
[TBL] [Abstract][Full Text] [Related]
3. Combined photothermal-chemotherapy of breast cancer by near infrared light responsive hyaluronic acid-decorated nanostructured lipid carriers.
Zheng S; Nguyen VD; Song SY; Han J; Park JO
Nanotechnology; 2017 Oct; 28(43):435102. PubMed ID: 28783035
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Lu Z; Su J; Li Z; Zhan Y; Ye D
Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
[TBL] [Abstract][Full Text] [Related]
5. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
6. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
7. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
8. Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy.
Lin M; Teng L; Wang Y; Zhang J; Sun X
Drug Deliv; 2016 May; 23(4):1420-5. PubMed ID: 26203688
[TBL] [Abstract][Full Text] [Related]
9. Biotin anchored nanostructured lipid carriers for targeted delivery of doxorubicin in management of mammary gland carcinoma through regulation of apoptotic modulator.
Tripathi CB; Parashar P; Arya M; Singh M; Kanoujia J; Kaithwas G; Saraf SA
J Liposome Res; 2020 Mar; 30(1):21-36. PubMed ID: 30741049
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo.
Dong X; Wang W; Qu H; Han D; Zheng J; Sun G
Drug Deliv; 2016 May; 23(4):1374-8. PubMed ID: 26208133
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery.
Gao X; Zhang J; Xu Q; Huang Z; Wang Y; Shen Q
Drug Dev Ind Pharm; 2017 Apr; 43(4):661-667. PubMed ID: 28043185
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
Li X; Jia X; Niu H
Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.
Cao C; Wang Q; Liu Y
Drug Des Devel Ther; 2019; 13():1087-1098. PubMed ID: 31118562
[No Abstract] [Full Text] [Related]
15. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
16. Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy.
Wang H; Sun G; Zhang Z; Ou Y
Biomed Pharmacother; 2017 Jul; 91():241-250. PubMed ID: 28460227
[TBL] [Abstract][Full Text] [Related]
17. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
[No Abstract] [Full Text] [Related]
19. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer gene therapy: Transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery.
Zhang B; Zhang Y; Yu D
Oncol Rep; 2017 Feb; 37(2):937-944. PubMed ID: 27959442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
